Altimmune (ALT) Stock Highlights

8.25 | +0.86%

2024-12-21 05:20:58

Altimmune Inc is a clinical-stage biopharmaceutical company focused on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The companys lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH (non-alcoholic steatohepatitis). In addition, Altimmune is developing HepTcell, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B virus (HBV).

Statistics

Range Today

8.18 8.75

Volume Today 4.89M

Range 1 Year

5.28 14.84

Volume 1 Year 1.03B

Range 3 Year

2.09 23.49

Volume 3 Year 2.21B

Range 10 Year

1.51 137.7

Volume 10 Year 3.42B

Highlights

Market Capitalization 545.83M (small)

Floating Shares 70.54M

Current Price 8.25

Price To Earnings -4.43

Price To Revenue 935.89

Price To Book 3.58

Earnings Per Share -1.68

Payout Ratio 0%

Performance

Latest +0.86%

1 Month +8.41%

3 Months +9.85%

6 Months +39.83%

1 Year +2.74%

3 Years -10.81%

5 Years +366.1%

10 Years -93.89%

Benchmarks

Market Capitalization

144 / 368

Gross Profits

216 / 278

Total Revenue

266 / 300

Total Rank

103 / 368

Free Cashflow

220 / 352

Performance 5 years

21 / 368

Obligatory risk notice

We would like to point out that the contents of this website are for general information purposes only and do not constitute recommendations for the purchase or sale of specific financial instruments, and therefore do not constitute investment advice. In particular, marketstorylabs.com and its creators cannot assess the extent to which information / recommendations made on the pages correspond to your investment objectives, your risk tolerance and your ability to bear losses. Therefore, if you make any investment decisions based on information on the site, you do so solely on your own responsibility and at your own risk. This in turn means that neither marketstorylabs.com nor its creators are liable for any losses incurred as a result of investment decisions based on the information on the marketstorylabs.com website or other media used.